Susan Minton

Biochemistry, Genetics and Molecular Biology · Life Sciences

25h-index4.3kcitations58works0.02yr avg
OpenAlex↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Breast Cancer Treatment Studies(10), HER2/EGFR in Cancer Research(9), Cancer Treatment and Pharmacology(9), Cancer Genomics and Diagnostics(7), Estrogen and related hormone effects(6)

Publications58 total

Supplementary Figure 1 from Evolutionary Approaches to Prolong Progression-Free Survival in Breast Cancer
2023Open Access
Supplementary Table 1 from Evolutionary Approaches to Prolong Progression-Free Survival in Breast Cancer
2023Open Access
Data from Evolutionary Approaches to Prolong Progression-Free Survival in Breast Cancer
2023Open Access
Supplementary Figure 1 from Evolutionary Approaches to Prolong Progression-Free Survival in Breast Cancer
2023Open Access
Supplementary Table 1 from Evolutionary Approaches to Prolong Progression-Free Survival in Breast Cancer
2023Open Access
Data from Evolutionary Approaches to Prolong Progression-Free Survival in Breast Cancer
2023Open Access
A first in man phase I trial of the oral immunomodulator, indoximod, combined with docetaxel in patients with metastatic solid tumors
UNC Libraries·2020Open Access
Gonadotropin-Releasing Hormone Agonists During Chemotherapy for Preservation of Ovarian Function and Fertility in Premenopausal Patients With Early Breast Cancer: A Systematic Review and Meta-Analysis of Individual Patient–Level Data
Journal of Clinical Oncology·2018· 366 citedOpen Access
Abstract CT042: Efficacy of T-DM1+pertuzumab over standard therapy for HER2+ breast cancer: Results from the neoadjuvant I-SPY 2 TRIAL
Cancer Research·2016· 17 cited
Abstract CT106: Efficacy of pertuzumab/trastuzumab/paclitaxel over standard trastuzumab/paclitaxel therapy for HER2+ breast cancer: Results from the neoadjuvant I-SPY 2 TRIAL
Cancer Research·2016· 10 cited
Phase I trial of gemcitabine plus trastuzumab and pertuzumab in previously treated metastatic HER2+ breast cancer.
Journal of Clinical Oncology·2016
A phase I study of indoximod in patients with advanced malignancies
Oncotarget·2016· 141 citedOpen Access
Exploiting evolutionary principles to prolong tumor control in preclinical models of breast cancer
Science Translational Medicine·2016· 326 cited
A phase I study of MK-5108, an oral aurora a kinase inhibitor, administered both as monotherapy and in combination with docetaxel, in patients with advanced or refractory solid tumors
Investigational New Drugs·2015· 43 citedOpen Access
Abstract P2-15-04: A phase 1/2 study of Ad.p53 DC vaccine with indoximod immunotherapy in metastatic breast cancer
Cancer Research·2015· 4 cited
The Neoadjuvant Model Is Still the Future for Drug Development in Breast Cancer
Clinical Cancer Research·2015· 90 citedOpen Access
Pilot study of Iyengar yoga for management of aromatase inhibitor-associated arthralgia in women with breast cancer
Psycho-Oncology·2015· 17 citedOpen Access
A first in man phase I trial of the oral immunomodulator, indoximod, combined with docetaxel in patients with metastatic solid tumors
Oncotarget·2014· 170 citedOpen Access
Triple-Negative Breast Cancer
Breast Disease·2014· 5 cited
Sweat but no gain: Inhibiting proliferation of multidrug resistant cancer cells with “ersatzdroges”
International Journal of Cancer·2014· 49 citedOpen Access
page 1 of 3Next →

Frequent Co-authors

Roohi Ismail‐Khan(16), Daniel M. Sullivan(13), Pamela N. Münster(10), Hatem Soliman(10), Hyo S. Han(9), Scott Antonia(8), Nicholas N. Vahanian(7), Yoonseok Kam(6), Robert A. Gatenby(6), Robert J. Gillies(5), Anthony Neuger(5), Howard Streicher(5), Paul B. Jacobsen(5), Stacy L. Moulder(5), Charles J. Link(5), Ji‐Hyun Lee(4), Richard Jove(4), M. Lacevic(4), Michelle Melisko(4), Kathy S. Albain(4)